India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

Under the terms of the agreement, Biocytogen will receive an upfront payment from BeOne Medicines. In addition, Biocytogen is ...

Singapore-headquartered financial technology company Ant International is "seriously considering" stablecoin license ...

Ichnos Glenmark Innovation & AbbVie ink exclusive global licensing agreement for ISB 2001: New York Saturday, July 12, 2025, 12:00 Hrs [IST] IGI Therapeutics SA, a wholly owned su ...

Shares of Glenmark Pharmaceuticals Ltd rose 10% to hit a 52-week high on Friday after the drugmaker’s New York-based ...

Namibia also became the first country to adopt India’s UPI digital payment system via a licensing agreement, and joined the ...

Elanco (ELAN) stock in focus as Australia's Neurizon Therapeutics (PAAFF) enters into a licensing deal with the company for ...

Special Report: Neurizon Therapeutics has inked an exclusive global licensing deal with New York Stock Exchange-listed Elanco Animal Health Incorporated and affiliates for monepantel, the active ...

AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, ...

Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive ...